NO20052952D0 - Farmasoytisk sammensetning som innbefatter mikropartikler - Google Patents

Farmasoytisk sammensetning som innbefatter mikropartikler

Info

Publication number
NO20052952D0
NO20052952D0 NO20052952A NO20052952A NO20052952D0 NO 20052952 D0 NO20052952 D0 NO 20052952D0 NO 20052952 A NO20052952 A NO 20052952A NO 20052952 A NO20052952 A NO 20052952A NO 20052952 D0 NO20052952 D0 NO 20052952D0
Authority
NO
Norway
Prior art keywords
microparticles
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
NO20052952A
Other languages
English (en)
Other versions
NO20052952L (no
Inventor
Jean-Daniel Bonny
Michael Ausborn
Holger Petersen
Rolf Lofler
Olivier Lambert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32299717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052952(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0226993A external-priority patent/GB0226993D0/en
Priority claimed from GB0227883A external-priority patent/GB0227883D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20052952D0 publication Critical patent/NO20052952D0/no
Publication of NO20052952L publication Critical patent/NO20052952L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20052952A 2002-11-19 2005-06-16 Farmasoytisk sammensetning som innbefatter mikropartikler NO20052952L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0226993A GB0226993D0 (en) 2002-11-19 2002-11-19 Organic compounds
GB0227883A GB0227883D0 (en) 2002-11-29 2002-11-29 Organic compounds
PCT/EP2003/012898 WO2004045633A2 (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles

Publications (2)

Publication Number Publication Date
NO20052952D0 true NO20052952D0 (no) 2005-06-16
NO20052952L NO20052952L (no) 2005-08-15

Family

ID=32299717

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052952A NO20052952L (no) 2002-11-19 2005-06-16 Farmasoytisk sammensetning som innbefatter mikropartikler

Country Status (16)

Country Link
US (6) US20040097419A1 (no)
EP (2) EP2377519B1 (no)
JP (2) JP2006514927A (no)
KR (2) KR101146471B1 (no)
AU (3) AU2003293700A1 (no)
BR (1) BR0316421A (no)
CA (1) CA2501978C (no)
CO (1) CO5690533A2 (no)
EC (1) ECSP055800A (no)
ES (1) ES2577613T3 (no)
MX (1) MXPA05005388A (no)
NO (1) NO20052952L (no)
PL (1) PL376015A1 (no)
PT (1) PT2377519E (no)
RU (2) RU2404748C2 (no)
WO (1) WO2004045633A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009801A2 (en) 2004-06-17 2006-01-26 Valera Pharmaceuticals, Inc. Compositions and methods for treating central precocious puberty
ES2323141T3 (es) * 2004-08-12 2009-07-07 Quest Pharmaceutical Services Composiciones farmaceuticas para el suministro por liberacion controlada de compuestos biologicamente activos.
WO2006065951A2 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
SI1787658T1 (sl) 2005-11-10 2012-07-31 Chemi Spa Formulacije z trajnim sproščanjem somatostatin analognih inhibitorjev rastnega hormona
KR20130024988A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
RU2463079C2 (ru) * 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
US8071537B2 (en) * 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
EP2317975B1 (en) 2008-06-25 2016-04-13 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
RU2678833C2 (ru) * 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
CA2737484C (en) 2008-09-18 2017-10-10 Surmodics Pharmaceuticals, Inc. Microencapsulation process with solvent and salt
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
CN106727448B (zh) * 2016-12-12 2020-10-13 广州中大南沙科技创新产业园有限公司 醋酸奥曲肽干粉吸入制剂及其制备方法
WO2018156202A1 (en) 2017-02-27 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-psychotic composition and treatment methods
WO2019155396A1 (en) * 2018-02-07 2019-08-15 Dr. Reddy's Laboratories Limited Sustained release microspheres with low initial burst and methods of preparation thereof
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CY1327A (en) 1979-11-27 1986-06-27 Sandoz Ag Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use
DE3032345C2 (de) * 1980-08-28 1984-06-28 Mathias 4815 Schloss Holte Mitter Lagerung einer Rakel mit seitlich außerhalb der Schablone eines Siebdruckwerkes angeordneten Lagern
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
GB9805417D0 (en) * 1998-03-14 1998-05-06 Core Technologies Limited Production of microparticles
FR2778100B1 (fr) * 1998-04-29 2001-05-04 Virsol Nouvelles microspheres a base de poly(methylidene malonate), leur procede de preparation et compositions pharmaceutiques les contenant
US6204308B1 (en) * 1999-03-01 2001-03-20 Novartis Ag Organic compounds
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
AU2002232824A1 (en) * 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents

Also Published As

Publication number Publication date
US20170281548A1 (en) 2017-10-05
RU2404748C2 (ru) 2010-11-27
AU2008200018A1 (en) 2008-01-31
RU2010144614A (ru) 2012-05-10
NO20052952L (no) 2005-08-15
KR20050086708A (ko) 2005-08-30
US20220273574A1 (en) 2022-09-01
MXPA05005388A (es) 2005-08-03
KR101146471B1 (ko) 2012-05-21
RU2005119632A (ru) 2006-05-10
US20040097419A1 (en) 2004-05-20
EP2377519B1 (en) 2016-03-23
CO5690533A2 (es) 2006-10-31
ES2577613T3 (es) 2016-07-15
AU2011200966B2 (en) 2013-08-01
KR20120032537A (ko) 2012-04-05
CA2501978A1 (en) 2004-06-03
KR101240071B1 (ko) 2013-03-06
EP2377519A3 (en) 2011-11-23
US20070122485A1 (en) 2007-05-31
WO2004045633A2 (en) 2004-06-03
JP2011256185A (ja) 2011-12-22
US20200009056A1 (en) 2020-01-09
PL376015A1 (en) 2005-12-12
JP5784402B2 (ja) 2015-09-24
HK1161123A1 (en) 2012-08-24
ECSP055800A (es) 2005-08-11
AU2003293700A1 (en) 2004-06-15
EP2377519A2 (en) 2011-10-19
AU2008200018B2 (en) 2010-12-09
JP2006514927A (ja) 2006-05-18
WO2004045633A3 (en) 2005-01-13
US20140323415A1 (en) 2014-10-30
PT2377519E (pt) 2016-06-09
EP1565161A2 (en) 2005-08-24
BR0316421A (pt) 2005-10-11
AU2011200966A1 (en) 2011-03-24
CA2501978C (en) 2013-12-17

Similar Documents

Publication Publication Date Title
ATE380544T1 (de) Umhüllte feste darreichungsform
PT1501534E (pt) Formulacoes farmaceuticas
EP1603593A4 (en) PHARMACEUTICAL COMPOSITION
DK3494995T3 (da) Superfin formoterolformulering
FI20011478A0 (fi) Farmaseuttinen koostumus
KR20050009999A (ko) 약제학적 제제
NO20052739D0 (no) CCR5-antagonister som medikamenter
DE60311307D1 (de) Shampoo-zusammensetzungen
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
DK1587478T3 (da) Farmaceutisk sammensætning
DE10393374D2 (de) Zusammensetzung
EE200300589A (et) Ravimkoostised
FI20022128A0 (fi) Farmaseuttinen koostumus
DE60316954D1 (de) Shampoozusammensetzungen
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
ATE448780T1 (de) Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
SE0500163L (sv) Sammansättning
IS7715A (is) Nýjar lyfjasamsetningar úr módafíníl
NO20043576L (no) Pharmaceutical formulation comprising melatonin
DE60326900D1 (de) Duftstoff-Zusammensetzung
EP1561467A4 (en) COMPOSITION FOR RECOVERING DAMAGED SKIN
IS7581A (is) Lyfjasamsetning
NO20044140D0 (no) New Composition
NO20044164L (no) Farmasoytiske sammensetninger

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application